{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000088","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.342633+00:00","generated_at":"2026-05-31T11:05:08.603464+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autolus Q2 net loss $58.3M; cash $705.9M; obe-cel PDUFA Nov 16, 2024 on track","bullets":["Net loss $58.3M ($0.22/sh) vs $45.6M ($0.26/sh) in Q2 2023; cash $705.9M up from $239.6M at Dec 31, 2023.","Obe-cel PDUFA target action date set at November 16, 2024; BLA under review by FDA.","FELIX data (median follow-up 21 mos): 40% of responders in ongoing remission without subsequent stem cell transplant.","MAA submitted to UK MHRA July 2024; EMA MAA accepted April 2024.","R&D expenses $36.6M, G&A $21.9M, both up on pre-commercialization activities and new manufacturing facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000088","json":"https://secwatch.observer/filing/0001730463-24-000088.json","markdown":"https://secwatch.observer/filing/0001730463-24-000088.md","text":"https://secwatch.observer/filing/0001730463-24-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000088/0001730463-24-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000088/autl-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:05:08.603464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}